Paper Details

  1. Home
  2. Paper Details

Randomized, double-blind study of prulifloxacin versus ciprofloxacin in patients with acute exacerbations of chronic bronchitis.

Author: , DionisioPaolo, GrassiCarlo, RosignoliMaria Teresa, SalvatoriEnrica

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This randomized, multicenter, double-blind, double-dummy trial assessed the efficacy and safety of prulifloxacin in comparison with ciprofloxacin in 235 patients with acute exacerbations of chronic bronchitis (AECB). Patients received either 600 mg prulifloxacin once daily or 500 mg ciprofloxacin twice a day for 10 days. Clinical success was observed in 84.7% and 85% of patients in the prulifloxacin and ciprofloxacin groups, respectively. The study showed that a 10-day course of prulifloxacin is as effective and safe as ciprofloxacin in the treatment of patients with AECB.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Recently the role of bacteria in acute exacerbations of chronic bronchitis (AECB) as well as antibiotic treatment with selected drugs, especially fluoroquinolones, have been better defined. OBJECTIVE: To assess the efficacy and safety in patients with AECB of prulifloxacin in comparison...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1159/000063623

データ提供：米国国立医学図書館（NLM）

Prulifloxacin vs. Ciprofloxacin: Evaluating Efficacy in Acute Exacerbations of Chronic Bronchitis

The world of respiratory medicine is constantly battling against the challenges of chronic bronchitis and its exacerbations. This randomized, double-blind study compares the efficacy and safety of prulifloxacin and ciprofloxacin, two fluoroquinolones commonly used to treat acute exacerbations of chronic bronchitis (AECB). The researchers sought to determine if these drugs offer comparable benefits for patients struggling with AECB.

Comparable Efficacy and Safety for AECB Treatment

The study found that both prulifloxacin and ciprofloxacin were equally effective in treating AECB, with similar clinical success rates and ability to eradicate common bacterial strains. Both drugs were also well-tolerated, with minimal adverse events. This finding suggests that both medications can be effective and safe options for treating AECB.

Broadening Treatment Options for AECB

This research provides valuable insights into the treatment of AECB, demonstrating that both prulifloxacin and ciprofloxacin are effective options for patients. It highlights the importance of having a range of treatment options available, allowing for personalized care based on individual patient needs and preferences.

Dr.Camel's Conclusion

This study offers valuable evidence for the effectiveness and safety of both prulifloxacin and ciprofloxacin in treating acute exacerbations of chronic bronchitis. It expands the therapeutic arsenal for managing this challenging condition, providing clinicians with more options to tailor treatment to individual patients.

Date :
  1. Date Completed 2003-05-22
  2. Date Revised 2017-11-01
Further Info :

Pubmed ID

12097764

DOI: Digital Object Identifier

10.1159/000063623

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.